UEG's content platform for gastroenterology education bringing recordings, courses, guidelines, and more together in one place.

Re-live UEG Week 2026 on Gutflix Gut Guide online What's new on Gutflix

Trending on Gutflix

Rate for better recommendations!

Your feedback helps us show you more of what you like and less of what you dislike!

More of this!

We will show you more similar content.

Not for me!

We won't suggest this again.

Bookmark!

Save this content for later!

New to myUEG? Create an account! Log In with myUEG account

UEG Poster

New

Audio / Video Poster

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

PERSISTENCE OF RISANKIZUMAB AND ADALIMUMAB IN THE TREATMENT OF CROHN’S DISEASE: A RETROSPECTIVE CANADIAN REAL-WORLD STUDY

Talat Bessissow 1, Neeraj Narula 2, Cynthia Seow 3, Melissa Horvat 4, Sarah-Jane Bull 4, Virginie Daviault 4, Jennifer O'Hara 4, Geneviève Paradis 4, Olivia Hughes 5, Matthias Hunger 6, Johan Dalén 7, John K. Marshall 2

Affiliations

1 McGill University, Montreal, Canada

2 McMaster University, Hamilton, Canada

3 University Of Calgary, Calgary, Canada

4 AbbVie Corporation, Saint-Laurent, Canada

5 ICON plc, Blue Bell, Pennsylvania, United States

6 ICON plc, Munich, Germany

7 ICON plc, Stockholm, Sweden

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

Risankizumab (RISA), an anti-interleukin (IL)-23p19 inhibitor, has demonstrated efficacy and safety in randomized controlled trials for the treatment of Crohn’s disease (CD).^1,2 However, real world evidence assessing treatment persistence with RISA, particularly in the context of other advanced therapies (ATs) such as adalimumab (ADA, anti-TNF) is limited. Treatment persistence may serve as a surrogate for sustained clinical efficacy and tolerability in routine clinical practice.

Aims & Methods

A retrospective, observational cohort study aimed to assess patient characteristics and treatment persistence with RISA or ADA in adults with CD enrolled in the Canadian AbbVie Care Patient Support Program (PSP). Enrolled patients initiated RISA between January 2023 and December 2024, or ADA between January 2017 and December 2019 (censored at the end of 2020 to avoid impact of subsequent non-medical switch policies). While participation is voluntary, the PSP is estimated to capture >90% of patients in Canada receiving these therapies. Data were collected from routine interactions with PSP personnel, including registered nurses; treatment and clinical management decisions remained at the discretion of prescribing physicians. Persistence over 12 months was estimated using Kaplan-Meier methods and defined as the duration from treatment initiation to discontinuation for any reason.

Results

Of 16,194 patients included in the analysis, 8,920 initiated RISA and 7,274 initiated ADA for CD. Among these, 28.2% and 75.4% were AT naïve, respectively. Patient characteristics are presented in Table 1. Median (range) follow-up duration was 12 (0-23) months for RISA and 20 (0-36) months for ADA. Among RISA patients, 6.3% received intravenous RISA rescue therapy and 2.3% received another form of dose adjustment during maintenance; whereas 41% of ADA patients received dose adjustment during maintenance. Overall, 6- and 12-month persistence was 0.92 (95% Confidence Interval: 0.92-0.93) and 0.83 (0.82-0.84) for RISA and 0.90 (0.90-0.91) and 0.80 (0.79-0.81) for ADA. Among AT naïve patients (2,514 on RISA and 5,484 on ADA), 6- and 12-month persistence was 0.94 (0.93-0.95) and 0.88 (0.86-0.89) for RISA and 0.91 (0.90-0.92) and 0.82 (0.81-0.83) for ADA.

Table 1. Patient characteristics
* Includes interval shortening/widening, dose escalation/de-escalation, or a combination of both dose and interval adjustments from the initial maintenance regimen ** Multiple responses possible
	Risankizumab N=8,920	Adalimumab N=7,274
Demographics
Age in years, mean (SD) Sex - Female, n (%) Location, n (%) - Rural - Urban - Unknown	48.05 (16.67) 4,699 (52.7) 1,476 (16.5) 7,060 (79.1) 384 (4.3)	43.80 (15.59) 3,778 (51.9) 1,161 (16.0) 4,786 (65.8) 1,327 (18.2)
Clinical characteristics
Harvey Bradshaw Index, mean (SD); n	6.71 (5.13); 4,153	6.68 (5.16); 2,403
Treatment characteristics
AT naïve, n (%) - Yes - No Number of prior ATs used, n (%) - 0 - 1 - 2 - 3 - ≥4 Any type of maintenance dose adjustments, n (%) - Yes - No Discontinued treatment, n (%) - Yes - No Reason for discontinuation*, n (%) - Death - Efficacy - Side effects - Physician choice - Other	2,514 (28.2) 6,406 (71.8) 2,514 (28.2) 2,694 (30.2) 2,115 (23.7) 1,044 (11.7) 553 (6.2) 202 (2.3) 8718 (97.7) 2,016 (22.6) 6,904 (77.4) 68 (3.4) 661 (32.8) 185 (9.2) 501 (24.9) 735 (36.5)	5,484 (75.4) 1,790 (24.6) 5,484 (75.4) 1,538 (21.1) 212 (2.9) 36 (0.5) 4 (0.1) 2,981 (41.0) 4,293 (59.0) 2,279 (31.3) 4,995 (68.7) 47 (2.1) 829 (36.4) 779 (34.2) 3 (0.1) 711 (31.2)

Conclusion

In these unadjusted analyses, CD patients receiving RISA in real-world practice demonstrated high treatment persistence, particularly among those who were AT naïve. Few RISA patients underwent dose adjustments during maintenance, and overall, treatment persistence was numerically higher than ADA treated patients. These observed findings may contribute to informing treatment decisions and improving patient care.

References

D’Haens G, et al. Lancet. 2022;399:2015–30.
Ferrante M, et al. Lancet. 2022;399:2031–46.

Disclosure

TB has received speaker, consultant and research support from Abbvie, Alimentiv, Bristol-Myers-Squibb, CSF Vifor, Celltrion, Eli Lilly, Ferring, Fresenius Kabi, Gilead, Iterative scope, Johnson and Johnson, Merck, Mirium, Pendopharm, Pentax, Pfizer, Roche, Sandoz, Sanofi, Takeda, Vial Pharma.
NN holds a McMaster University AFP Clinician Researcher Award and has received honoraria from Janssen, Abbvie, Takeda, Pfizer, Sandoz, Novartis, Iterative Health, Innomar Strategies, Fresenius Kabi, Amgen, Organon, Eli Lilly, and Ferring.
CS has participated in advisory boards and has been invited as a speaker by Janssen, Abbvie, Takeda, Lilly, Ferring, Merck, Pfizer, Organon, Sandoz, Pharmascience, Fresenius Kabi, Amgen, Celltrion, Sanofi, GSK, Biocon.
MH, S-JB, VD, JRO and GP are full-time employees of AbbVie and may own stock and options.
OH, MH and JD are full-time employees of ICON plc, which acted as a consultant to AbbVie on this study.
JKM has been a consultant to AbbVie, Alimentiv, Amgen, Avir Pharma, Bausch Health, Biocon, Bristol Myers Squibb, Celltrion, Ferring, Fresenius Kabi, GlaxoSmithKline, Janssen, Lilly, Merck, Organon, Pfizer, Pharmascience, Regeneron, Roche, Sandoz, Sanofi, Takeda, and has been invited as a speaker by AbbVie, Amgen, Bausch Health, Biocon, Ferring, Fresenius Kabi, Janssen, Lupin, Merck, Organon, Pfizer, Pharmascience, Roche, Takeda.

Conference

UEG Week Barcelona 2026

Topics

IBD

Submission format

Abstract

Session

IBD (INCLUDING MICROSCOPIC COLITIS) (Posters)

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

Compensated advanced chronic liver disease and clinically significant portal hypertension: From non-invasive diagnosis to treatment

Annalisa Berzigotti

PERSISTENCE OF RISANKIZUMAB AND ADALIMUMAB IN THE TREATMENT OF CROHN’S DISEASE: A RETROSPECTIVE CANADIAN REAL-WORLD STUDY

John K. Marshall

Panel discussion: Advanced chronic liver disease: When the liver gets stiff, the complications get going

COMPARATIVE STUDY ON THE EFFECTIVENESS, DURABILITY, AND SAFETY OF UPADACITINIB VERSUS RISANKIZUMAB AFTER ANTI-TNF FAILURE IN CROHN'S DISEASE: THE U-PARIS STUDY OF ENEIDA

Fernando Bermejo

SPINE AND SACROILIAC JOINT INVOLVEMENT IN NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE - SYMPTOMS, CLINICAL AND MAGNETIC RESONANCE IMAGING FINDINGS FROM A POPULATION-BASED COHORT STUDY

Mikkel Østergaard

DIFFERENT COOKING METHODS ALTER HOST AND GUT MICROBIAL METABOLISM, A RANDOMIZED CROSS-OVER DIETARY TRIAL IN HEALTHY VOLUNTEERS

João Sabino

Age (years) at the start of the treatment, median (IQR) Median age at Crohn’s disease diagnosis, years (IQR) Median time of follow-up, months (IQR) Crohn’s disease duration (months), median (IQR)	41 (30-51) 26 (20-38) 8 (4-15) 104 (40-213)	51 (35-62) 39 (38-52) 10 (6-14) 98 (47-193)
Male sex, n (%) Current smoker, n (%)	145 (60) 46 (19)	161 (51) 82 (26)
EIMs, n (%) IMIDs, n (%) Comorbidities, n (%)	101 (42) 23 (11) 53 (22)	80 (25) 40 (14) 125 (39)
Crohn’s disease extent, n (%) L1: ileal L2: colonic L3: ileocolonic L4: upper GI tract	103 (43) 29 (12) 109 (44) 1 (1)	201 (62) 17 (5) 101 (32) 1 (1)
Crohn’s disease behaviour, n (%) B1: inflammatory B2: stricturing B2-B3: stricturing-fistulizing B3: fistulizing	143 (59) 54 (22) 12 (5) 33 (14)	152 (48) 106 (33) 26 (8) 35 (11)
Perianal disease, n (%)	101 (42)	80 (25)
Previous immunosuppressor, n (%) Previous biologic agents, n (%) Anti-TNF Infliximab Adalimumab Certolizumab Vedolizumab Ustekinumab	137 (62) 94 (39) 191 (79) 3 (1) 9 (4) 83 (35)	182 (59) 86 (27) 259 (81) 0 (0) 12 (4) 122 (38)
Previous surgery due to Crohn’s disease, n (%) Abdominal Perianal	79 (33) 58 (24) 32 (13)	112 (36) 93 (29) 25 (8)
Immunomodulators at baseline, n (%) Corticosteroids at baseline, n (%) Treatment line, n (%) Second-line Third-line After 2 anti-TNF After 1 anti-TNF + vedolizumab After 1 anti-TNF + ustekinumab	37 (15) 37 (15) 111 (46) 43 (18) 8 (3) 80 (33)	46 (15) 46 (14) 156 (49) 30 (9) 14 (4) 120 (38)
HBI at baseline, median (IQR) FC levels at baseline (μg/g), median (IQR) Endoscopic activity at baseline, n/n’ (%) Mild Moderate Severe Radiologic activity at baseline, n/n’ (%)	6 (3-10) 545 (195-1,234) 17/98 (17) 35/98 (36) 46/98 (47) 85/98 (87)	5 (2-11) 536 (217-1,237) 10/94 (10) 32/94 (35) 52/94 (55) 139/147 (95)